{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:45:55Z","timestamp":1782747955902,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010806","name":"Amgen Nederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010806","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018503","name":"InfraRedx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018503","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Myocardial infarction (MI) induces an inflammatory response that may be amenable to targeted therapy. This cohort study evaluated the systemic inflammatory burden across different infarct sizes using serial measurements of C-reactive protein (CRP), interleukin-6 (IL-6), and targeted inflammatory proteomics (Olink\u2019s Target 96 Inflammation panel) during hospitalization and up to 12\u00a0weeks post-MI. Baseline IL-6\u00a0concentrations were progressively higher with increasing infarct size, with differential temporal trajectories observed across infarct size strata (\n                    <jats:italic>P<\/jats:italic>\n                    for interaction\u2009&lt;\u20090.001), a finding confirmed by proteomic analysis (\n                    <jats:italic>P<\/jats:italic>\n                    <jats:sub>\n                      <jats:italic>adj<\/jats:italic>\n                    <\/jats:sub>\n                    for interaction\u2009=\u20090.009). Patients with small infarct size showed no significant changes in CRP or IL-6 concentrations, yet demonstrated downregulation of urokinase (uPA) and upregulation of angiogenesis-related proteins (tumor necrosis factor-related weak inducer of apoptosis [TWEAK] and hepatocyte growth factor [HGF]), similar to those observed in patients with moderate or large infarct sizes, emphasizing the biological significance of these processes. Overall, greater myocardial injury was associated with higher inflammatory burden, highlighting IL-6 as a promising therapeutic target for acute anti-inflammatory treatment after large MI.\n                  <\/jats:p>","DOI":"10.1007\/s12265-026-10801-8","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:08:14Z","timestamp":1782745694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Immediate Impact of Infarct Size on the Systemic Inflammatory Response: IL-6 as Central Mediator Identified through Biomarker and Proteomic Profiling"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6731-0965","authenticated-orcid":false,"given":"Jonathan","family":"Los","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans B.","family":"Mensink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"Bulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse H.","family":"Hol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysun","family":"Cetinyurek-Yavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels P.","family":"Riksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saloua","family":"El Messaoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"Cornel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2943-5932","authenticated-orcid":false,"given":"Robert-Jan M.","family":"van Geuns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"2","key":"10801_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/eurheartj\/ehad486","volume":"45","author":"MA Matter","year":"2024","unstructured":"Matter MA, Paneni F, Libby P, Frantz S, St\u00e4hli BE, Templin C, et al. Inflammation in acute myocardial infarction: the good, the bad and the ugly. Eur Heart J. 2024;45(2):89\u2013103. https:\/\/doi.org\/10.1093\/eurheartj\/ehad486.","journal-title":"Eur Heart J"},{"issue":"5","key":"10801_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrcardio.2014.28","volume":"11","author":"NG Frangogiannis","year":"2014","unstructured":"Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014;11(5):255\u201365. https:\/\/doi.org\/10.1038\/nrcardio.2014.28.","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"10801_CR3","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1161\/01.cir.0000049742.68848.99","volume":"107","author":"JA de Lemos","year":"2003","unstructured":"de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003;107(5):690\u20135. https:\/\/doi.org\/10.1161\/01.cir.0000049742.68848.99.","journal-title":"Circulation"},{"issue":"5","key":"10801_CR4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jacbts.2024.01.019","volume":"9","author":"A Paccalet","year":"2024","unstructured":"Paccalet A, Badawi S, Pillot B, Augeul L, Mechtouff L, Harhous Z, et al. <article-title update=\u201cadded\u201d>Deleterious anti-inflammatory macrophage recruitment in early post-infarction phase. JACC Basic Transl Sci. 2024;9(5):593\u2013604. https:\/\/doi.org\/10.1016\/j.jacbts.2024.01.019.","journal-title":"JACC Basic Transl Sci"},{"issue":"12","key":"10801_CR5","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1161\/01.cir.0000012625.02748.62","volume":"105","author":"C Mueller","year":"2002","unstructured":"Mueller C, Buettner HJ, Hodgson JM, Marsch S, Perruchoud AP, Roskamm H, et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation. 2002;105(12):1412\u20135. https:\/\/doi.org\/10.1161\/01.cir.0000012625.02748.62.","journal-title":"Circulation"},{"issue":"10","key":"10801_CR6","doi-asserted-by":"publisher","first-page":"e005637","DOI":"10.1161\/jaha.117.005637","volume":"6","author":"CL Fanola","year":"2017","unstructured":"Fanola CL, Morrow DA, Cannon CP, Jarolim P, Lukas MA, Bode C, et al. Interleukin-6 and the risk of adverse outcomes in patients after an acute coronary syndrome: observations from the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) trial. J Am Heart Assoc. 2017;6(10):e005637. https:\/\/doi.org\/10.1161\/jaha.117.005637.","journal-title":"J Am Heart Assoc."},{"issue":"1","key":"10801_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11883-024-01259-7","volume":"27","author":"NN Mehta","year":"2024","unstructured":"Mehta NN, deGoma E, Shapiro MD. IL-6 and cardiovascular risk: a narrative review. Curr Atheroscler Rep. 2024;27(1):12. https:\/\/doi.org\/10.1007\/s11883-024-01259-7.","journal-title":"Curr Atheroscler Rep"},{"issue":"15","key":"10801_CR8","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","volume":"77","author":"K Broch","year":"2021","unstructured":"Broch K, Anstensrud AK, Woxholt S, Sharma K, T\u00f8llefsen IM, Bendz B, et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2021;77(15):1845\u201355. https:\/\/doi.org\/10.1016\/j.jacc.2021.02.049.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10801_CR9","doi-asserted-by":"publisher","first-page":"e38077","DOI":"10.1016\/j.heliyon.2024.e38077","volume":"10","author":"FB Mensink","year":"2024","unstructured":"Mensink FB, Los J, Oemrawsingh RM, von Birgelen C, Ijsselmuiden A, Meuwissen M, et al. Functional and morphological improvement of significant non-culprit coronary artery stenosis by LDL-C reduction with a PCSK9 antibody: rationale and design of the randomized FITTER trial. Heliyon. 2024;10(19):e38077. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38077.","journal-title":"Heliyon"},{"issue":"16","key":"10801_CR10","doi-asserted-by":"publisher","first-page":"910","DOI":"10.4244\/eij-d-24-01065","volume":"21","author":"FB Mensink","year":"2025","unstructured":"Mensink FB, Los J, Reda Morsy MM, Oemrawsingh RM, von Birgelen C, Ijsselmuiden AJJ, et al. Changes in non-culprit coronary lesions with PCSK9 inhibitors: the randomised, placebo-controlled FITTER trial. EuroIntervention. 2025;21(16):910\u201320. https:\/\/doi.org\/10.4244\/eij-d-24-01065.","journal-title":"EuroIntervention"},{"key":"10801_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-026-02869-8","author":"J Los","year":"2026","unstructured":"Los J, Mensink FB, Reda Morsy MM, Nishimiya K, Oemrawsingh RM, Ij AJJ, et al. Short-term lesion-level impact of extensive LDL-C reduction with statins and PCSK9 inhibitors: a pre-specified subgroup analysis of the randomized FITTER trial. Clin Res Cardiol. 2026. https:\/\/doi.org\/10.1007\/s00392-026-02869-8.","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"10801_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jcin.2008.04.010","volume":"1","author":"S Chia","year":"2008","unstructured":"Chia S, Senatore F, Raffel OC, Lee H, Wackers FJ, Jang IK. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2008;1(4):415\u201323. https:\/\/doi.org\/10.1016\/j.jcin.2008.04.010.","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"10801_CR13","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jacc.2005.12.003","volume":"47","author":"A Halkin","year":"2006","unstructured":"Halkin A, Stone GW, Grines CL, Cox DA, Rutherford BD, Esente P, et al. Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol. 2006;47(5):951\u201361. https:\/\/doi.org\/10.1016\/j.jacc.2005.12.003.","journal-title":"J Am Coll Cardiol"},{"key":"10801_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15243229","author":"P Ruile","year":"2025","unstructured":"Ruile P, Brado J, Kaier K, Schmitt R, Hein M, N\u00fchrenberg T, et al. Myocardial scar and cardiac biomarker levels as predictors of mortality after acute myocardial infarction: a CMR-based long-term study. Diagnostics (Basel). 2025. https:\/\/doi.org\/10.3390\/diagnostics15243229.","journal-title":"Diagnostics (Basel)"},{"issue":"8","key":"10801_CR15","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1161\/atvbaha.123.319272","volume":"43","author":"JM Kraaijenhof","year":"2023","unstructured":"Kraaijenhof JM, Opstal TSJ, Cornel JH, Gill D, Hovingh GK, Catapano AL, et al. Effect of PCSK9 inhibition on the plasma proteome: a SPIRE substudy. Arterioscler Thromb Vasc Biol. 2023;43(8):1595\u20137. https:\/\/doi.org\/10.1161\/atvbaha.123.319272.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10801_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.118.034645","volume":"138","author":"AD Pradhan","year":"2018","unstructured":"Pradhan AD, Aday AW, Rose LM, Ridker PM. Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy. Circ. 2018;138(2):141\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034645.","journal-title":"Circ"},{"key":"10801_CR17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.atherosclerosis.2019.07.015","volume":"288","author":"M Ruscica","year":"2019","unstructured":"Ruscica M, Tokgozoglu L, Corsini A, Sirtori CR. PCSK9 inhibition and inflammation: a narrative review. Atherosclerosis. 2019;288:146\u201355. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.07.015.","journal-title":"Atherosclerosis"},{"issue":"5","key":"10801_CR18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jacc.2013.05.016","volume":"62","author":"O Yousuf","year":"2013","unstructured":"Yousuf O, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, Nasir K, et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013;62(5):397\u2013408. https:\/\/doi.org\/10.1016\/j.jacc.2013.05.016.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10801_CR19","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/s44161-025-00700-7","volume":"4","author":"L Zhang","year":"2025","unstructured":"Zhang L, Omarov M, Xu L, deGoma E, Natarajan P, Georgakis MK. IL6 genetic perturbation mimicking IL-6 inhibition is associated with lower cardiometabolic risk. Nat Cardiovasc Res. 2025;4(9):1172\u201386. https:\/\/doi.org\/10.1038\/s44161-025-00700-7.","journal-title":"Nat Cardiovasc Res"},{"issue":"5","key":"10801_CR20","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448\u201357. https:\/\/doi.org\/10.1038\/ni.3153.","journal-title":"Nat Immunol"},{"key":"10801_CR21","doi-asserted-by":"publisher","first-page":"1255533","DOI":"10.3389\/fimmu.2023.1255533","volume":"14","author":"E Grebenciucova","year":"2023","unstructured":"Grebenciucova E, VanHaerents S. Interleukin 6: at the interface of human health and disease. Front Immunol. 2023;14:1255533. https:\/\/doi.org\/10.3389\/fimmu.2023.1255533.","journal-title":"Front Immunol"},{"issue":"1","key":"10801_CR22","doi-asserted-by":"publisher","first-page":"e0245684","DOI":"10.1371\/journal.pone.0245684","volume":"16","author":"T Bochaton","year":"2021","unstructured":"Bochaton T, Lassus J, Paccalet A, Derimay F, Rioufol G, Prieur C, et al. Association of myocardial hemorrhage and persistent microvascular obstruction with circulating inflammatory biomarkers in STEMI patients. PLoS ONE. 2021;16(1):e0245684. https:\/\/doi.org\/10.1371\/journal.pone.0245684.","journal-title":"PLoS ONE"},{"issue":"8","key":"10801_CR23","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ejim.2004.07.013","volume":"15","author":"AS Gabriel","year":"2004","unstructured":"Gabriel AS, Martinsson A, Wretlind B, Ahnve S. IL-6 levels in acute and post myocardial infarction: their relation to CRP levels, infarction size, left ventricular systolic function, and heart failure. Eur J Intern Med. 2004;15(8):523\u20138. https:\/\/doi.org\/10.1016\/j.ejim.2004.07.013.","journal-title":"Eur J Intern Med"},{"issue":"4","key":"10801_CR24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1161\/circresaha.116.310527","volume":"120","author":"PM Ridker","year":"2017","unstructured":"Ridker PM. How common is residual inflammatory risk? Circ Res. 2017;120(4):617\u20139. https:\/\/doi.org\/10.1161\/circresaha.116.310527.","journal-title":"Circ Res"},{"issue":"11","key":"10801_CR25","doi-asserted-by":"publisher","first-page":"e012638","DOI":"10.1161\/jaha.119.012638","volume":"8","author":"JJ Carrero","year":"2019","unstructured":"Carrero JJ, Andersson Franko M, Obergfell A, Gabrielsen A, Jernberg T. HsCRP level and the risk of death or recurrent cardiovascular events in patients with myocardial infarction: a healthcare-based study. J Am Heart Assoc. 2019;8(11):e012638. https:\/\/doi.org\/10.1161\/jaha.119.012638.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10801_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/ehjacc\/zuab110","volume":"11","author":"C Tiller","year":"2022","unstructured":"Tiller C, Reindl M, Holzknecht M, Lechner I, Schwaiger J, Brenner C, et al. Association of plasma interleukin-6 with infarct size, reperfusion injury, and adverse remodelling after ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2022;11(2):113\u201323. https:\/\/doi.org\/10.1093\/ehjacc\/zuab110.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"1","key":"10801_CR27","doi-asserted-by":"publisher","first-page":"17269","DOI":"10.1038\/s41598-024-68333-7","volume":"14","author":"E Maaniitty","year":"2024","unstructured":"Maaniitty E, Jalkanen J, Sinisilta S, Gunn J, Vasankari T, Biancari F, et al. Differential circulating cytokine profiles in acute coronary syndrome versus stable coronary artery disease. Sci Rep. 2024;14(1):17269. https:\/\/doi.org\/10.1038\/s41598-024-68333-7.","journal-title":"Sci Rep"},{"issue":"1","key":"10801_CR28","doi-asserted-by":"publisher","first-page":"5564","DOI":"10.1038\/s41598-025-90240-8","volume":"15","author":"A Bj\u00f6rkenheim","year":"2025","unstructured":"Bj\u00f6rkenheim A, Sunnefeldt E, Finke K, Smith DR, Fr\u00f6bert O, Brasier N. Biomarkers of inflammation in sweat after myocardial infarction. Sci Rep. 2025;15(1):5564. https:\/\/doi.org\/10.1038\/s41598-025-90240-8.","journal-title":"Sci Rep"},{"issue":"1","key":"10801_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/s0021-9150(02)00062-x","volume":"164","author":"H Ma","year":"2002","unstructured":"Ma H, Calderon TM, Fallon JT, Berman JW. Hepatocyte growth factor is a survival factor for endothelial cells and is expressed in human atherosclerotic plaques. Atherosclerosis. 2002;164(1):79\u201387. https:\/\/doi.org\/10.1016\/s0021-9150(02)00062-x.","journal-title":"Atherosclerosis"},{"issue":"30","key":"10801_CR30","doi-asserted-by":"publisher","first-page":"13264","DOI":"10.1073\/pnas.1005183107","volume":"107","author":"WD Tolbert","year":"2010","unstructured":"Tolbert WD, Daugherty-Holtrop J, Gherardi E, Vande Woude G, Xu HE. Structural basis for agonism and antagonism of hepatocyte growth factor. Proc Natl Acad Sci U S A. 2010;107(30):13264\u20139. https:\/\/doi.org\/10.1073\/pnas.1005183107.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10801_CR31","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1160\/th11-10-0711","volume":"107","author":"R Madonna","year":"2012","unstructured":"Madonna R, Cevik C, Nasser M, De Caterina R. Hepatocyte growth factor: molecular biomarker and player in cardioprotection and cardiovascular regeneration. Thromb Haemost. 2012;107(4):656\u201361. https:\/\/doi.org\/10.1160\/th11-10-0711.","journal-title":"Thromb Haemost"},{"issue":"1","key":"10801_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1600-065X.2011.01054.x","volume":"244","author":"LC Burkly","year":"2011","unstructured":"Burkly LC, Michaelson JS, Zheng TS. TWEAK\/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev. 2011;244(1):99\u2013114. https:\/\/doi.org\/10.1111\/j.1600-065X.2011.01054.x.","journal-title":"Immunol Rev"},{"issue":"1","key":"10801_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/01.cir.90.1.61","volume":"90","author":"PA Merlini","year":"1994","unstructured":"Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90(1):61\u20138. https:\/\/doi.org\/10.1161\/01.cir.90.1.61.","journal-title":"Circulation"},{"key":"10801_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010337","author":"AA Ismail","year":"2021","unstructured":"Ismail AA, Shaker BT, Bajou K. The plasminogen-activator plasmin system in physiological and pathophysiological angiogenesis. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms23010337.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10801_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2011.10.044","volume":"222","author":"B Fuhrman","year":"2012","unstructured":"Fuhrman B. The urokinase system in the pathogenesis of atherosclerosis. Atherosclerosis. 2012;222(1):8\u201314. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.10.044.","journal-title":"Atherosclerosis"},{"issue":"1","key":"10801_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrm2821","volume":"11","author":"HW Smith","year":"2010","unstructured":"Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010;11(1):23\u201336. https:\/\/doi.org\/10.1038\/nrm2821.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"10801_CR37","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1182\/blood-2002-03-0778","volume":"100","author":"AE May","year":"2002","unstructured":"May AE, Schmidt R, Kanse SM, Chavakis T, Stephens RW, Sch\u00f6mig A, et al. Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction. Blood. 2002;100(10):3611\u20137. https:\/\/doi.org\/10.1182\/blood-2002-03-0778.","journal-title":"Blood"},{"issue":"10","key":"10801_CR38","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.amjcard.2009.12.059","volume":"105","author":"A Abbate","year":"2010","unstructured":"Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GG, Van Tassell BW, Robati R, et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol. 2010;105(10):1371-7.e1. https:\/\/doi.org\/10.1016\/j.amjcard.2009.12.059.","journal-title":"Am J Cardiol"},{"issue":"10","key":"10801_CR39","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.amjcard.2013.01.287","volume":"111","author":"A Abbate","year":"2013","unstructured":"Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013;111(10):1394\u2013400. https:\/\/doi.org\/10.1016\/j.amjcard.2013.01.287.","journal-title":"Am J Cardiol"},{"issue":"5","key":"10801_CR40","doi-asserted-by":"publisher","first-page":"e014941","DOI":"10.1161\/jaha.119.014941","volume":"9","author":"A Abbate","year":"2020","unstructured":"Abbate A, Trankle CR, Buckley LF, Lipinski MJ, Appleton D, Kadariya D, et al. Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment-elevation myocardial infarction. J Am Heart Assoc. 2020;9(5):e014941. https:\/\/doi.org\/10.1161\/jaha.119.014941.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10801_CR41","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","volume":"36","author":"AC Morton","year":"2015","unstructured":"Morton AC, Rothman AM, Greenwood JP, Gunn J, Chase A, Clarke B, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J. 2015;36(6):377\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehu272.","journal-title":"Eur Heart J"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-026-10801-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-026-10801-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-026-10801-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:08:15Z","timestamp":1782745695000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-026-10801-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["10801"],"URL":"https:\/\/doi.org\/10.1007\/s12265-026-10801-8","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Niels P. Riksen is financially supported by a consortium grant of the Dutch Heart Foundation (AtheroNeth; 01\u2013001-2024\u20130601) and a Vici grant of the Netherlands Organization for Health Research and Development (ZonMw; 09150182410037).Robert-Jan M. van Geuns reports consulting and speaker fees from Abbott Vascular and Astra Zeneca, and received institutional research grants from Amgen, InfraRedx, Astra Zeneca, and Sanofi.The remaining authors report no relationships that could be construed as a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration. Informed consent was obtained from all patients for being included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Subjects\/Informed Consent Statement"}}],"article-number":"79"}}